4523.T
Eisai Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 4,811.00
+1.67%Price chart
Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
23.2x
EV/EBITDA
13.9x
Market Cap
JPY 1.36T
MomentumView details →
1D Return
+1.67%
YTD Return
+0.73%
RSI (14)
47.3
ValuationView details →
P/E (Fwd)
23.2x
EV/EBITDA
13.9x
Market Cap
JPY 1.36T
RSI (14)
47.3
MomentumView details →
1D Return
+1.67%
YTD Return
+0.73%
Similar companies
Latest newsMore news →
Eisai announced that China approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early Alzheimer's disease, enabling at-home administration.2d agoCanada's Drug Agency issued a final positive recommendation supporting public reimbursement of Eisai's LEQEMBI (lecanemab) for early Alzheimer's disease.4d agoChina's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.8d ago